Baseline characteristics and posttransplantation course summary
| . | Patient (UPN) . | ||
|---|---|---|---|
| 1 . | 2 . | 3 . | |
| Pretransplantation patient characteristic | |||
| Age, y/sex | 55/M | 39/F | 51/M |
| Diagnosis/remission | AML/CR2 | Burkitt lymphoma/CR2 | Plasmablastic lymphoma/CR2 |
| Duration of HIV infection, y | 20 | 11 | 1 |
| HCT-CI score/KPS | 3/80 | 3/80 | 4/80 |
| Stem cell donor | Sibling donor | Unrelated donor | Unrelated donor |
| Conditioning regimen | Flu/Bu | Flu/Bu/ATG | Flu/Bu/ATG |
| GVHD prophylaxis | MTX/tacrolimus | MTX/tacrolimus | MTX/tacrolimus |
| HAART during transplantation | Atazanavir, lamivudine, tenofovir | Efavirenz, emtricitabine/tenofovir | Efavirenz, emtricitabin/tenofovir |
| Transplantation outcome | |||
| Response | CR | CR | CR |
| Alive | Yes | Yes | Yes |
| OS, days | +802 | +368 | +651 |
| PFS, days | +802 | +160 | +651 |
| Acute GVHD grade | 0 | 0 | II |
| Chronic GVHD | Extensive | Limited | Limited |
| Current IST | None | None | None |
| Current KPS | 100 | 90 | 100 |
| Posttransplantation immune reconstitution and HIV control | |||
| CD4 count, cells/μL | |||
| Baseline | 457 | 339 | 189 |
| Day +90 | N/A | 174 | 472 |
| Day +180 | 450 | N/A | 867 |
| Day +365 | 397 | 270 | 616 |
| Beyond 1 y | 549 | — | 675 |
| CD8 count, cells/μL | |||
| Baseline | 1039 | 421 | 656 |
| Day +90 | N/A | 957 | 3781 |
| Day +180 | 589 | N/A | 2138 |
| Day +365 | 366 | 3532 | 2545 |
| Beyond 1 y | 650 | — | 2507 |
| Lymphoid/myeloid chimerism, % | |||
| Day +30 | 26/100 | 90/100 | 90/100 |
| Day +180 | 69/100 | 100/100 | 100/100 |
| Day +360 | 100/90 | 100/100 | 100/100 |
| HIV RNA viral load | |||
| Pretransplantation | 814 copies/mL | Undetectable | Undetectable |
| Day +30 | Undetectable | Undetectable | Undetectable |
| Day +90 | Undetectable | Undetectable | Undetectable |
| Day +180 | Undetectable | Undetectable | Undetectable |
| Day +365 | Undetectable | Undetectable | Undetectable |
| Beyond 1 y | 363 copies/mL | — | Undetectable |
| Other infections | EBV reactivation (day +90) | Candida glabrata fungemia (day +3); CMV reactivation (day +26); Klebsiella oxytoca UTI (day +31) | Enterobacter agglomerans bacteremia (day +108); MRSA bacteremia, catheter-associated (day +133) |
| . | Patient (UPN) . | ||
|---|---|---|---|
| 1 . | 2 . | 3 . | |
| Pretransplantation patient characteristic | |||
| Age, y/sex | 55/M | 39/F | 51/M |
| Diagnosis/remission | AML/CR2 | Burkitt lymphoma/CR2 | Plasmablastic lymphoma/CR2 |
| Duration of HIV infection, y | 20 | 11 | 1 |
| HCT-CI score/KPS | 3/80 | 3/80 | 4/80 |
| Stem cell donor | Sibling donor | Unrelated donor | Unrelated donor |
| Conditioning regimen | Flu/Bu | Flu/Bu/ATG | Flu/Bu/ATG |
| GVHD prophylaxis | MTX/tacrolimus | MTX/tacrolimus | MTX/tacrolimus |
| HAART during transplantation | Atazanavir, lamivudine, tenofovir | Efavirenz, emtricitabine/tenofovir | Efavirenz, emtricitabin/tenofovir |
| Transplantation outcome | |||
| Response | CR | CR | CR |
| Alive | Yes | Yes | Yes |
| OS, days | +802 | +368 | +651 |
| PFS, days | +802 | +160 | +651 |
| Acute GVHD grade | 0 | 0 | II |
| Chronic GVHD | Extensive | Limited | Limited |
| Current IST | None | None | None |
| Current KPS | 100 | 90 | 100 |
| Posttransplantation immune reconstitution and HIV control | |||
| CD4 count, cells/μL | |||
| Baseline | 457 | 339 | 189 |
| Day +90 | N/A | 174 | 472 |
| Day +180 | 450 | N/A | 867 |
| Day +365 | 397 | 270 | 616 |
| Beyond 1 y | 549 | — | 675 |
| CD8 count, cells/μL | |||
| Baseline | 1039 | 421 | 656 |
| Day +90 | N/A | 957 | 3781 |
| Day +180 | 589 | N/A | 2138 |
| Day +365 | 366 | 3532 | 2545 |
| Beyond 1 y | 650 | — | 2507 |
| Lymphoid/myeloid chimerism, % | |||
| Day +30 | 26/100 | 90/100 | 90/100 |
| Day +180 | 69/100 | 100/100 | 100/100 |
| Day +360 | 100/90 | 100/100 | 100/100 |
| HIV RNA viral load | |||
| Pretransplantation | 814 copies/mL | Undetectable | Undetectable |
| Day +30 | Undetectable | Undetectable | Undetectable |
| Day +90 | Undetectable | Undetectable | Undetectable |
| Day +180 | Undetectable | Undetectable | Undetectable |
| Day +365 | Undetectable | Undetectable | Undetectable |
| Beyond 1 y | 363 copies/mL | — | Undetectable |
| Other infections | EBV reactivation (day +90) | Candida glabrata fungemia (day +3); CMV reactivation (day +26); Klebsiella oxytoca UTI (day +31) | Enterobacter agglomerans bacteremia (day +108); MRSA bacteremia, catheter-associated (day +133) |
ATG indicates antithymocyte globulin; Bu, busulfan; CMV, cytomegalovirus; CR, complete remission; EBV, Epstein-Barr virus; Flu, fludarabine; GVHD, graft-versus-host disease; HAART, high active antiretroviral therapy; HCT-CI, hematopoietic cell transplantation comorbidity index; IST, immunosuppressive therapy; KPS, Karnofsky performance score; MTX, methotrexate; MRSA, methicillin-resistant Staphylococcus aureus; N/A, not available; OS, overall survival; PFS, progression-free survival; UPN, unique patient number; and UTI, urinary tract infection.